Elicio Therapeutics, Inc. (ELTX)
Company Description
Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases.
For therapies designed to engage the immune system to treat disease, it is critical to target activation at the unique location where adaptive immune responses are generated.
Our proprietary Amphiphile, or AMP, platform delivers immunotherapeutics directly to the “brain center” of the immune system - the lymph nodes. We believe this site-specific delivery of disease-specific antigens, adjuvants, and other immunomodulators will more efficiently educate, activate, and amplify critical immune cells, resulting in induction and persistence of potent adaptive immunity required to treat many diseases.
Our lead product candidate, ELI-002, is being developed to treat cancers driven by KRAS, a mutation found in approximately 25% of tumors. We are conducting a Phase 1/2 clinical trial of ELI-002 (AMPLIFY-201) and anticipate initial safety, dose escalation, and correlative biomarker data in the first half of 2022.
We are also evaluating the potential use of ELI-004, our universal AMP-modified CpG adjuvant, and a component of ELI-002, in conjunction with other disease-specific antigens, to treat or prevent additional diseases.
| Country | United States |
| Founded | 2011 |
| Industry | Pharmaceutical Preparations |
| Sector | Biotechnology |
| Employees | 22 |
| CEO | Robert Connelly |
Contact Details
Address:
One Kendall Square, Building 1400 West, Suite 14303 Cambridge, MA 02139 United States | |
| Phone | (857) 209-0050 |
| Website | elicio.com |
Stock Details
| Ticker Symbol | ELTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| CIK Code | 1555192 |
Key Executives
| Name | Position |
|---|---|
| Robert Connelly | Chief Executive Officer, President and Director |
| Daniel Geffken | Interim Chief Financial Officer and Director |
| Christopher Haqq, M.D., Ph.D. | Executive Vice President, Head of Research and Development and Chief Medical Officer |
| Annette Matthies, Ph.D. | Chief Business Officer |
| Julian Adams, Ph.D. | Chairman and Director |
| Carol Ashe | Director |
| Ofer Gonen | Director |
| Daphne Karydas | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 27, 2022 | D | Notice of Exempt Offering of Securities |
| Nov 18, 2021 | D/A | Notice of Exempt Offering of Securities |
| Nov 12, 2021 | D/A | Notice of Exempt Offering of Securities |
| Oct 19, 2021 | D | Notice of Exempt Offering of Securities |
| Jul 13, 2021 | S-1/A | General form for registration of securities under the Securities Act of 1933 |
| Jun 29, 2021 | S-1/A | General form for registration of securities under the Securities Act of 1933 |
| Jun 28, 2021 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 9, 2021 | DRS/A | Draft Registration Statement |
| Apr 23, 2021 | DRS | Draft Registration Statement |
| Jul 15, 2020 | D | Notice of Exempt Offering of Securities |